{Reference Type}: Journal Article {Title}: GEIS 2013 guidelines for gastrointestinal sarcomas (GIST). {Author}: Poveda A;del Muro XG;López-Guerrero JA;Martínez V;Romero I;Valverde C;Cubedo R;Martín-Broto J; {Journal}: Cancer Chemother Pharmacol {Volume}: 74 {Issue}: 5 {Year}: Nov 2014 {Factor}: 3.288 {DOI}: 10.1007/s00280-014-2547-0 {Abstract}: Gastrointestinal stromal tumors (GIST) are the most common mesenchymal soft tissue sarcoma of the gastrointestinal tract. Correct diagnosis with thorough use of pathologic and molecular tools of GIST mutations has been of the foremost importance. GIST are usually (95 %) KIT positive and harbor frequent KIT or platelet-derived growth factor receptor α-activating mutations. This deep molecular understanding has allowed the correct classification into risk groups with implications regarding prognosis, essential use in the development of targeted therapies and even response prediction to this drugs. Treatment has been evolving and an update to include lessons learned from recent trials in advanced disease as well as controversies in the adjuvant setting that are changing daily practice, is reviewed here. An effort from the Spanish Group for Sarcoma Research with investigators from the group has been undertaken to launch this third version of the GIST guidelines and provide a practical means for the different disciplines that treat this complex disease.